Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
329000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the Series 8 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
Number of shares delivered during the month: 329,000 shares (329,000 new shares and 0 treasury shares transferred)
EVO FUND (the allottee of the previously issued Series 8 stock acquisition rights)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio for the month: 3.9%; exercise ratio subject to the exercise restriction: 3.6%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise price during the month ranged from ¥542 to ¥612. Details of the exercise price adjustment clause and the lower limit of the adjustment: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 85,000; unexercised rights as of the end of the month preceding the month under review: 60,690; unexercised rights as of month-end: 57,400
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The number of shares delivered across all series was 329,000, the number of listed shares as of the payment date for the issuance was 9,252,901, and the exercise ratio subject to the exercise restriction was 3.6%.
Most recent equity financing
Timing 12 December 2025 / Type Series 8 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the Series 8 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 329,000 shares (329,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee of the previously issued Series 8 stock acquisition rights) |
| Dilution Rate | Exercise ratio for the month: 3.9%; exercise ratio subject to the exercise restriction: 3.6% |
| Total number of issued shares | 11,683,901 shares (as of the end of the month preceding the month under review) → Not disclosed |
| Exercise price | The exercise price during the month ranged from ¥542 to ¥612. Details of the exercise price adjustment clause and the lower limit of the adjustment: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 85,000; unexercised rights as of the end of the month preceding the month under review: 60,690; unexercised rights as of month-end: 57,400 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restriction under Article 434 of the Listing Regulations. The number of shares delivered across all series was 329,000, the number of listed shares as of the payment date for the issuance was 9,252,901, and the exercise ratio subject to the exercise restriction was 3.6%. |
| Most recent equity financing | Timing 12 December 2025 / Type Series 8 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in April 2026 of the Series 8 stock acquisition rights issued on 12 December 2025.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.